CN116063301A - 一种苯并噻唑衍生物荧光探针及其制备方法和应用 - Google Patents
一种苯并噻唑衍生物荧光探针及其制备方法和应用 Download PDFInfo
- Publication number
- CN116063301A CN116063301A CN202310069641.1A CN202310069641A CN116063301A CN 116063301 A CN116063301 A CN 116063301A CN 202310069641 A CN202310069641 A CN 202310069641A CN 116063301 A CN116063301 A CN 116063301A
- Authority
- CN
- China
- Prior art keywords
- benzothiazole derivative
- probe
- fluorescent probe
- fluorescent
- derivative fluorescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 94
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title abstract description 7
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims abstract description 18
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims abstract description 17
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- 241000252212 Danio rerio Species 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000003384 imaging method Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000219195 Arabidopsis thaliana Species 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 abstract description 75
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract description 25
- 230000005284 excitation Effects 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 3
- 230000009977 dual effect Effects 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 56
- 238000000799 fluorescence microscopy Methods 0.000 description 34
- 239000004201 L-cysteine Substances 0.000 description 28
- 235000013878 L-cysteine Nutrition 0.000 description 28
- 238000012632 fluorescent imaging Methods 0.000 description 19
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000002189 fluorescence spectrum Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000012447 hatching Effects 0.000 description 4
- 229910020366 ClO 4 Inorganic materials 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 241000219194 Arabidopsis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101000937647 Drosophila melanogaster Probable malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124976 antitubercular drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
- C09K2211/1037—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with sulfur
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1092—Heterocyclic compounds characterised by ligands containing sulfur as the only heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
技术领域
本发明属于有机合成领域,具体涉及苯并噻唑衍生物荧光探针及其制备方法和应用。
背景技术
硫化氢(H2S)是一种众所周知的具有臭鸡蛋气味的有毒易燃气体。最近的证据表明H2S与一氧化氮(NO)和一氧化碳(CO)一起作为重要的信号分子,参与许多病理生理和生理过程。在亚细胞水平上,线粒体是H2S的主要代谢位点,调节线粒体能量生成和氧化还原稳态功能。此外,H2S浓度异常与线粒体功能障碍密切相关,可引起许多神经退行性疾病和心血管疾病。另一方面,联氨(N2H4)因其易燃易爆的特性而成为著名的火箭推进燃料。此外,由于其强亲核性和还原性,N2H4也被应用于各个工业领域作为重要的化学材料。但N2H4毒性较大,经口腔和皮肤摄取N2H4可损伤肝脏、呼吸系统和中枢神经系统。一些抗结核药与异烟肼共用是治疗结核病的特征性药物,可代谢生成肼。此外,需要注意的是,N2H4通过线粒体损伤诱导细胞毒性,包括抑制单胺氧化酶,破坏内部稳态,以及干扰克雷布斯循环中的酮酸裂解酶。因此,开发有效的工具来监测线粒体H2S和N2H4水平就显得尤为重要。
近年来,荧光分子探针技术由于具有灵敏度高、操作简单、成本低等特点,已经成为检测重要金属离子,阴离子和小分子的重要手段。但现有绝大多数荧光探针仅能单独检测H2S或N2H4,无法同时检测H2S和N2H4,限制了其进一步实际应用。
有鉴于此,特提出本发明。
发明内容
针对现有技术中存在的问题,本发明考虑到苯并噻唑衍生物优异的光化学和光物理特性,合成了一种高灵敏度、高选择性的硫化氢和水合肼荧光探针。
本发明的主要目的在于提供一种用于双发射荧光增强检测硫化氢和水合肼的启动检测的线粒体靶向荧光探针;另一目的是提供该荧光探针的制备方法和应用。
为实现上述目的,本发明采用以下技术方案:
一种苯并噻唑衍生物荧光探针,具有HBT-P-T所示结构式:
;
其中,X=I、Cl。
所述苯并噻唑衍生物荧光探针的制备方法包括以下步骤:
S1:将HBT-P和三乙胺溶解于有机溶剂中;
S2:将S1所得溶液在室温下搅拌反应10分钟;
S3:将S2所得溶液加入2-噻吩甲酰氯,然后在室温下搅拌1小时;
S4:将S3所得溶液用二氯甲烷和水萃取,然后旋蒸除去溶剂,再用乙醇重结晶,即得到所述苯并噻唑衍生物荧光探针;
反应路线如下所示:
;
其中,X=I、Cl。
进一步地,所述步骤S1中有机溶剂为二氯甲烷。
进一步地,步骤S1中,加入的HBT-P和三乙胺的摩尔比为1:2。
进一步地,步骤S3中,加入的HBT-P和2-噻吩甲酰氯的摩尔比为1:3。
进一步地,具体制备方法为:将0.29gHBT-P和0.17 mL三乙胺溶于10 mL二氯甲烷中,室温下搅拌10分钟,然后加入0.26g 2-噻吩甲酰氯室温下搅拌1小时,用二氯甲烷和水萃取,然后旋蒸除去溶剂,再用乙醇重结晶,得到所述苯并噻唑衍生物荧光探针。
本发明还提供上述一种苯并噻唑衍生物荧光探针的用途,即在作为硫化氢和水合肼荧光探针方面的应用,特别是在活细胞、斑马鱼以及拟南芥中实时成像。该探针能应用于PBS:DMSO (v:v=8:2)体系中,同时进行硫化氢和水合肼的测定,并能应用于细胞成像、斑马鱼和拟南芥成像。
与现有技术相比,本发明的优点和积极效果在于:
本发明通过缩合反应制备苯并噻唑衍生物荧光探针,原料易得,合成和后处理方法简单。在多种常见阴离子及活性氧化物等物种中,对硫化氢和水合肼表现出较高荧光识别功能。探针可以检测硫化氢和水合肼两种物质,具有广泛的潜在应用价值。
附图说明
图1为本发明实施例1制得的苯并噻唑衍生物荧光探针1H NMR谱图。
图2为本发明实施例1制得的苯并噻唑衍生物荧光探针13C NMR谱图。
图3为本发明实施例1制得的苯并噻唑衍生物荧光探针的质谱谱图。
图4 a)为本发明实施例1制得的苯并噻唑衍生物荧光探针(1×10-5mol/L)的PBS:DMSO (v:v=8:2)溶液 (0.02 mol/L,pH =5)分别加入1×10-4mol/L分析物(F-, Cl-, I-,ClO4 -, PO4 3-, SO4 2-, HSO4 -, HSO3 -, ClO-, H2O2, Ca2+, Mg2+, Fe3+, Al3+, L-半胱氨酸(L-Cys), 谷胱甘肽, 甲胺, 盐酸羟胺, 乙二胺, 二甲胺, 正丁胺, 吡啶, N2H4, H2S)荧光光谱图(激发波长为415 nm);b)为本发明实施例1制得的苯并噻唑衍生物荧光探针(1×10- 5mol/L)的PBS:DMSO (v:v=8:2)溶液 (0.02 mol/L,pH =5)分别加入1×10-4mol/L分析物(F-, Cl-, I-, ClO4 -, PO4 3-, SO4 2-, HSO4 -, HSO3 -, ClO-, H2O2, Ca2+, Mg2+, Fe3+, Al3+,L-Cys, 谷胱甘肽, 甲胺, 盐酸羟胺, 乙二胺, 二甲胺, 正丁胺, 吡啶, N2H4, H2S)荧光光谱图(激发波长为475nm)。
图5 a)为本发明实施例1制得的苯并噻唑衍生物荧光(1×10-5mol/L)的PBS:DMSO(v:v= 8:2)溶液 (0.02 mol/L,pH =5)滴定不同浓度H2S的荧光光谱图,插图表示485nm处荧光强度随硫化氢浓度线性变化趋势图(激发波长为415nm); b)为本发明实施例1制得的苯并噻唑衍生物荧光(1×10-5mol/L)的PBS:DMSO (v:v, 8:2)溶液(0.02 mol/L,pH =5)滴定不同浓度H2S的荧光光谱图,插图表示590nm处荧光强度随硫化氢浓度线性变化趋势图(激发波长为475nm); c)为本发明实施例1制得的苯并噻唑衍生物荧光(1×10-5mol/L)的PBS:DMSO (v:v=8:2)溶液 (0.02 mol/L,pH =5)滴定不同浓度N2H4的荧光光谱图,插图表示515nm处荧光强度随水合肼浓度线性变化趋势图(激发波长为415nm)。
图6为Hela细胞中,苯并噻唑衍生物荧光探针与H2S的荧光成像图;Hela细胞用1×10-5mol/L荧光探针培育30分钟后加入1×10-4mol/L H2S,L-Cys, 和L-Cys+N-乙基马来酰亚胺(NEM),继续培育30分钟后,使用Olympus FV500-IX70激光共聚焦显微镜进行荧光成像;
其中:a, f, k, p分别为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM明场图;b, g, l, q为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM蓝色通道荧光成像图;c, h, m, r为上述荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM红色通道荧光成像图;d, i, n, s为b和c、g和h、l和m、q和r荧光成像图叠加后的图片;e, j, o, t为a b c、fg h、k l m、p q r荧光成像图叠加后的图片。
图7为Hela细胞中,苯并噻唑衍生物荧光探针与N2H4的荧光成像图;Hela细胞用1×10-5mol/L荧光探针培育30分钟后加入1×10-4mol/L N2H4,和1×10-3mol/L异烟肼(INH),继续培育30分钟后,使用Olympus FV500-IX70激光共聚焦显微镜进行荧光成像;
其中:a, f, k分别为荧光探针、探针+N2H4、探针+INH明场图;b, g, l为荧光探针、探针+N2H4、探针+INH蓝色通道荧光成像图;c, h, m为上述荧光探针、探针+N2H4、探针+INH红色通道荧光成像图;d, i, n为b和c、g和h、l和m荧光成像图叠加后的图片;e, j, o, t为a b c、f g h、k l m荧光成像图叠加后的图片。
图8为斑马鱼中,苯并噻唑衍生物荧光探针与H2S的荧光成像图;斑马鱼用1×10- 5mol/L荧光探针培育30分钟后加入1×10-4mol/L H2S, L-Cys, 和L-Cys+NEM,继续培育30分钟后,使用Olympus FV500-IX70激光共聚焦显微镜进行荧光成像;
其中:a, f, k, p分别为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM明场图;b, g, l, q为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM蓝色通道荧光成像图;c, h, m, r为上述荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM红色通道荧光成像图;d, i, n, s为b和c、g和h、l和m、q和r荧光成像图叠加后的图片;e, j, o, t为a b c、fg h、k l m、p q r荧光成像图叠加后的图片。
图9为斑马鱼中,苯并噻唑衍生物荧光探针与N2H4的荧光成像图;斑马鱼用1×10- 5mol/L荧光探针培育30分钟后加入1×10-4mol/L N2H4, 和1×10-3mol/L INH,继续培育30分钟后,使用OlympusFV500-IX70激光共聚焦显微镜进行荧光成像;
其中:a, f, k分别为荧光探针、探针+N2H4、探针+INH明场图;b, g, l为荧光探针、探针+N2H4、探针+INH蓝色通道荧光成像图;c, h, m为上述荧光探针、探针+N2H4、探针+INH红色通道荧光成像图;d, i, n为b和c、g和h、l和m荧光成像图叠加后的图片;e, j, o为a bc、f g h、k l m荧光成像图叠加后的图片。
图10为拟南芥根尖中,苯并噻唑衍生物荧光探针与N2H4的荧光成像图;拟南芥根尖用1×10-5mol/L荧光探针培育30分钟后加入1×10-4mol/L N2H4,和1×10-3mol/L INH,继续培育30分钟后,使用Olympus FV500-IX70激光共聚焦显微镜进行荧光成像;
其中:a, f, k分别为荧光探针、探针+N2H4、探针+INH明场图;b, g, l为荧光探针、探针+N2H4、探针+INH蓝色通道荧光成像图;c, h, m为上述荧光探针、探针+N2H4、探针+INH红色通道荧光成像图;d, i, n为b和c、g和h、l和m荧光成像图叠加后的图片;e, j, o为a bc、f g h、k l m荧光成像图叠加后的图片。
具体实施方式
下面结合附图和具体实施例进一步详细说明本发明,但本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限定本发明的范围。本发明实施例采用的试剂和原料为常规市场购买得到。
实施例1
本实施例1苯并噻唑衍生物荧光探针的制备方法如下:
将0.29g HBT-P(0.60mmol,HBT-P为已知化合物,参考文献方法合成)和0.17 mL(1.20 mmol)三乙胺溶于10 mL二氯甲烷中,室温下搅拌10分钟,然后加入0.26g 2-噻吩甲酰氯(1.80mmol)室温下搅拌1小时,用二氯甲烷和水萃取,然后旋蒸除去溶剂,再用乙醇重结晶,得到所述苯并噻唑衍生物荧光探针。反应路线如下所示:
;
其中,X=I、Cl。
采用核磁共振仪对制得的苯并噻唑衍生物进行核磁共振分析,结果如下:
1H NMR (400 MHz, DMSO-
d 6) δ 8.84-8.86 (d, 2H), 8.18-8.20 (m, 4H),8.17- 8.10 (m, 2H), 8.02 (s, 1H),7.88-7.92 (d, 1H), 7.64-7.73 (dd, 2H), 7.44-7.53 (m, 2H), 7.38-7.40 (t, 1H), 4.25 (s, 3H), 2.54 (s, 3H)。具体核磁共振氢图谱见图1;
13C NMR (101 MHz, DMSO-
d 6 ) δ 162.17, 160.63, 152.90, 151.97, 145.91,144.44, 137.61, 136.52, 136.47, 135.09, 133.14, 132.55, 132.03, 131.11,130.67, 129.32, 127.79, 127.25, 127.12, 126.40, 124.46, 123.22, 122.68,47.62, 20.94.具体核磁共振碳谱见图2;
质谱ESI-MS:m/z=469.0955。具体质谱图谱见图3。
实施例2
苯并噻唑衍生物荧光探针对硫化氢和水合肼的光学性质测定
将上述实施例1制得的苯并噻唑衍生物作为荧光探针在高水体积分数(PBS/DMSO=8/2)的溶液中配成摩尔浓度为2×10-5mol/L的溶液,分别在含摩尔浓度2×10-4mol/L(F-,Cl-, I-, ClO4 -, PO4 3-, SO4 2-, HSO4 -, HSO3 -, ClO-, H2O2, Ca2+, Mg2+, Fe3+, Al3+, L-Cys, 谷胱甘肽, 甲胺, 盐酸羟胺, 乙二胺, 二甲胺, 正丁胺, 吡啶, N2H4, H2S)的溶液中加入等体积的上述荧光探针溶液,采用荧光光谱仪进行分析(a)激发波长415nm; b)激发波长475nm;c)激发波长415nm),所得的荧光光谱图见图4。通过图4可以看出,本发明制得的苯并噻唑衍生物荧光探针只对硫化氢和水合肼具有明显响应,荧光信号可用于硫化氢和水合肼的快速鉴别,其他待测物无变化。
将上述实施例1制得的苯并噻唑衍生物作为荧光探针在高水体积分数(PBS/DMSO=8/2)的溶液中配成摩尔浓度为1×10-5mol/L的溶液,逐步加入0.1mol/L的H2S或N2H4水溶液(总加入量不超过苯并噻唑衍生物溶液体积分数的2%),控制H2S和N2H4在检测体系的最终浓度分别为2.0×10-4和2.5×10-4mol/L。从图5a和图5b可以看出,随着H2S浓度增加,探针在415 nm和475 nm光激发下,485nm和590 nm处荧光强度逐渐增加。图5c显示,随着N2H4浓度增加,探针在415 nm光激发下,510 nm处荧光强度逐渐增加。通过计算可以得出H2S检出限为0.90 nM, N2H4检出限为23.60 nM,因此本发明制得的苯并噻唑衍生物荧光探针可用于硫化氢和水合肼的荧光定量检测。
实施例3
苯并噻唑衍生物荧光探针在细胞内硫化氢和水合肼的检测试验
Hela细胞用1×10-5mol/L的上述实施例1制得的苯并噻唑衍生物荧光探针在37℃下培育30分钟后加入1×10-4mol/L H2S, L-Cys, 和L-Cys+NEM,继续培育30分钟后,使用Olympus FV500-IX70激光共聚焦显微镜进行荧光成像,具体如图6所示。其中:a, f, k, p分别为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM明场图;b, g, l, q为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM蓝色通道荧光成像图;c, h, m, r为上述荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM红色通道荧光成像图;d, i, n, s为b和c、g和h、l和m、q和r荧光成像图叠加后的图片;e, j, o, t为a b c、f g h、k l m、p q r荧光成像图叠加后的图片。细胞孵化探针后蓝色通道和红色通道均无明显荧光信号。再孵化H2S或L-Cys (刺激细胞产生内源性H2S),蓝色通道和红色通道均有明显荧光增强。而同时孵化L-Cys和NEM (内源性H2S抑制剂)的细胞蓝色通道和红色通道荧光信号消失。上述现象说明苯并噻唑衍生物荧光探针能够检测细胞内外源性H2S。
HeLa细胞用1×10-5mol/L的上述实施例1制得的苯并噻唑衍生物荧光探针在37℃下培育30分钟后加入1×10-4mol/L N2H4, 和1×10-3mol/L INH,继续培育30分钟后,使用OlympusFV500-IX70激光共聚焦显微镜进行荧光成像,具体如图7所示。其中:a, f, k分别为荧光探针、探针+N2H4、探针+INH明场图;b, g, l为荧光探针、探针+N2H4、探针+INH蓝色通道荧光成像图;c, h, m为上述荧光探针、探针+N2H4、探针+INH红色通道荧光成像图;d, i,n为b和c、g和h、l和m荧光成像图叠加后的图片;e, j, o, t为a b c、f g h、k l m荧光成像图叠加后的图片。细胞孵化探针后蓝色通道无荧光信号。再孵化N2H4或INH (被细胞代谢后产生N2H4),蓝色通道荧光显著增强,说明苯并噻唑衍生物荧光探针能够检测活细胞内N2H4。
实施例4
苯并噻唑衍生物荧光探针在斑马鱼内硫化氢和水合肼的检测试验
斑马鱼用1×10-5mol/L的上述实施例1制得的苯并噻唑衍生物荧光探针在28℃下培育30分钟后加入1×10-4mol/L H2S, L-Cys, 和 L-Cys+NEM,继续培育30分钟后,使用Olympus FV500-IX70激光共聚焦显微镜进行荧光成像,具体如图8所示。其中:a, f, k, p分别为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM明场图;b, g, l, q为荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM蓝色通道荧光成像图;c, h, m, r为上述荧光探针、探针+H2S、探针+L-Cys、探针+L-Cys+NEM红色通道荧光成像图;d, i, n, s为b和c、g和h、l和m、q和r荧光成像图叠加后的图片;e, j, o, t为a b c、f g h、k l m、p q r荧光成像图叠加后的图片。斑马鱼孵化探针后蓝色通道和红色通道均无明显荧光信号。再孵化H2S或L-Cys后蓝色通道和红色通道均有明显荧光增强。而同时孵化L-Cys和NEM蓝色通道和红色通道荧光信号消失。上述现象说明苯并噻唑衍生物荧光探针能够检测动物体内H2S。
斑马鱼用1×10-5mol/L的上述实施例1制得的苯并噻唑衍生物荧光探针在28℃下培育30分钟后加入1×10-4mol/L N2H4, 和1×10-3mol/L INH,继续培育30分钟后,使用OlympusFV500-IX70激光共聚焦显微镜进行荧光成像,具体如图9所示。其中:a, f, k分别为荧光探针、探针+N2H4、探针+INH明场图;b, g, l为荧光探针、探针+N2H4、探针+INH蓝色通道荧光成像图;c, h, m为上述荧光探针、探针+N2H4、探针+INH红色通道荧光成像图;d, i,n为b和c、g和h、l和m荧光成像图叠加后的图片;e, j, o, t为a b c、f g h、k l m荧光成像图叠加后的图片。细胞孵化探针后蓝色通道无荧光信号。再孵化N2H4或INH (被细胞代谢后产生N2H4),蓝色通道荧光显著增强,说明苯并噻唑衍生物荧光探针能够检测动物体内N2H4。
实施例5
苯并噻唑衍生物荧光探针在拟南芥内水合肼的检测试验
拟南芥用1×10-5mol/L的上述实施例1制得的苯并噻唑衍生物荧光探针在28℃下培育30分钟后加入1×10-4mol/L N2H4, 和 1×10-3mol/L INH,继续培育30分钟后,使用OlympusFV500-IX70激光共聚焦显微镜进行荧光成像,具体如图9所示。其中:a, f, k分别为荧光探针、探针+N2H4、探针+INH明场图;b, g, l为荧光探针、探针+N2H4、探针+INH蓝色通道荧光成像图;c, h, m为上述荧光探针、探针+N2H4、探针+INH红色通道荧光成像图;d, i,n为b和c、g和h、l和m荧光成像图叠加后的图片;e, j, o为a b c、f g h、k l m荧光成像图叠加后的图片。拟南芥孵化探针后蓝色通道和红色通道均无明显荧光信号。再孵化H2S后蓝色通道和红色通道均有明显荧光增强。而孵化N2H4后只有蓝色通道荧光增强。上述现象说明苯并噻唑衍生物荧光探针能够检测植物体内H2S和N2H4。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,其保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内,本发明的保护范围以权利要求书为准。
Claims (10)
1.一种苯并噻唑衍生物荧光探针,其特征在于,所述苯并噻唑衍生物荧光探针具有HBT-P-T所示结构式:
;
其中,X=I、Cl。
2.根据权利要求1所述的苯并噻唑衍生物荧光探针的制备方法,其特征在于,包括如下步骤:
S1:将HBT-P和三乙胺溶解于有机溶剂中;
S2:将S1所得溶液在室温下搅拌反应;
S3:将S2所得溶液加入2-噻吩甲酰氯,然后在室温下搅拌反应;
S4:将S3所得溶液用二氯甲烷和水萃取,然后旋蒸除去溶剂,再用乙醇重结晶,即得到所述苯并噻唑衍生物荧光探针;
反应路线如下所示:
;
其中,X=I、Cl。
3.根据权利要求2所述的苯并噻唑衍生物荧光探针的制备方法,其特征在于:所述步骤S1中加入的HBT-P,和三乙胺的摩尔比为1:2。
4.根据权利要求2所述的苯并噻唑衍生物荧光探针的制备方法,其特征在于:所述步骤S1中的有机溶剂为二氯甲烷,以0.6mmolHBT-P为基准,需要有机溶剂10mL。
5.根据权利要求2所述的苯并噻唑衍生物荧光探针的制备方法,其特征在于:所述步骤S2中的反应搅拌时间为10分钟。
6.根据权利要求2所述的苯并噻唑衍生物荧光探针的制备方法,其特征在于:所述步骤S3中加入的HBT-P和2-噻吩甲酰氯的摩尔比为1:3。
7.根据权利要求2所述的苯并噻唑衍生物荧光探针的制备方法,其特征在于:所述步骤S3中的反应搅拌时间为1小时。
8.根据权利要求2所述的苯并噻唑衍生物荧光探针的制备方法,其特征在于步骤如下:将0.29g HBT-P和0.17 mL三乙胺溶于10 mL二氯甲烷中,室温下搅拌10分钟,然后加入0.26g 2-噻吩甲酰氯室温下搅拌1小时,用二氯甲烷和水萃取,然后旋蒸除去溶剂,再用乙醇重结晶,得到所述苯并噻唑衍生物荧光探针。
9.根据权利要求1所述的苯并噻唑衍生物荧光探针作为硫化氢和水合肼荧光探针在细胞成像中的应用。
10.根据权利要求9所述的应用,其特征在于:所述苯并噻唑衍生物荧光探针在斑马鱼和拟南芥成像中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310069641.1A CN116063301B (zh) | 2023-02-07 | 2023-02-07 | 一种苯并噻唑衍生物荧光探针及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310069641.1A CN116063301B (zh) | 2023-02-07 | 2023-02-07 | 一种苯并噻唑衍生物荧光探针及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116063301A true CN116063301A (zh) | 2023-05-05 |
CN116063301B CN116063301B (zh) | 2024-05-24 |
Family
ID=86172864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310069641.1A Active CN116063301B (zh) | 2023-02-07 | 2023-02-07 | 一种苯并噻唑衍生物荧光探针及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116063301B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015002081A1 (ja) * | 2013-07-05 | 2015-01-08 | 富士フイルム株式会社 | 光電変換素子、色素増感太陽電池、金属錯体色素、配位子、色素溶液、色素吸着電極および色素増感太陽電池の製造方法 |
CN115232116A (zh) * | 2022-07-25 | 2022-10-25 | 河南理工大学 | 一种苯并噁唑-部花菁衍生物荧光探针及其制备方法和应用 |
-
2023
- 2023-02-07 CN CN202310069641.1A patent/CN116063301B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015002081A1 (ja) * | 2013-07-05 | 2015-01-08 | 富士フイルム株式会社 | 光電変換素子、色素増感太陽電池、金属錯体色素、配位子、色素溶液、色素吸着電極および色素増感太陽電池の製造方法 |
CN115232116A (zh) * | 2022-07-25 | 2022-10-25 | 河南理工大学 | 一种苯并噁唑-部花菁衍生物荧光探针及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
DONGLEI SHI ET AL: ""Evaluation of HOCl-generating anticancer agents by an ultrasensitive dual-mode fluorescent probe"", 《CHEM.SCI》, vol. 13, 4 March 2019 (2019-03-04), pages 3715 - 3722 * |
Also Published As
Publication number | Publication date |
---|---|
CN116063301B (zh) | 2024-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qiu et al. | A fluorescent sensor based on aggregation-induced emission: highly sensitive detection of hydrazine and its application in living cell imaging | |
Fu et al. | Fluorescent schiff base probes for sequential detection of Al3+ and F− and cell imaging applications | |
Shen et al. | A sensitive fluorescent probe for cysteine and Cu2+ based on 1, 8-naphthalimide derivatives and its application in living cells imaging | |
Shi et al. | Turn on fluorescent detection of hydrazine with a 1, 8-naphthalimde derivative | |
CN113234068B (zh) | 一种近红外花菁类比色荧光探针及其制备方法和应用 | |
CN108383823B (zh) | 萘并吡喃卡巴腙衍生物及其制备方法和应用 | |
CN109722241A (zh) | 一种识别铜离子和汞离子的双功能荧光探针及其制备方法和应用 | |
CN107698557B (zh) | 基于吡啶联吡唑酰腙衍生物的荧光探针及其制备方法和应用 | |
Kan et al. | Fe (III) induced fluorescent probe based on triamine and rhodamine derivatives and its applications in biological imaging | |
CN113061109B (zh) | 吗啉-吡啶-部花菁衍生物荧光探针及其制备方法和应用 | |
CN107382977B (zh) | 基于吡嗪联吡唑酰腙衍生物的荧光探针及其制备方法和应用 | |
CN110467621A (zh) | 一种小分子荧光探针及其制备方法与应用 | |
CN116063301B (zh) | 一种苯并噻唑衍生物荧光探针及其制备方法和应用 | |
CN107686479B (zh) | 一种近红外荧光探针化合物及其制备方法和应用 | |
CN107628997B (zh) | 一种基于喹啉衍生物的荧光探针及其制备方法和应用 | |
CN109810692B (zh) | 一种基于3-氨基吡嗪酰腙衍生物的荧光探针及其制备方法和应用 | |
CN107474825A (zh) | 基于三氮唑酰腙衍生物的荧光探针及其制备方法和应用 | |
CN114907336B (zh) | 一种基于苯并噻唑的锌离子荧光探针及其制备方法与应用 | |
CN110818702B (zh) | 一种吡啶-香豆素衍生物荧光探针及其制备方法和应用 | |
CN113788821B (zh) | 近红外联氨化合物、制备方法以及甲醛检测试剂盒和应用 | |
CN106243085B (zh) | 基于喹啉骨架的铜离子和硫离子双靶点荧光探针及其制备方法和应用 | |
CN113025313A (zh) | 吗啉-吡啶-部花菁衍生物作为硫化氢荧光探针的应用 | |
Li et al. | A novel viscosity‐sensitive fluorescent probe for monitoring the changes of mitochondrial viscosity | |
CN109721592B (zh) | 一种含香豆素的氨基吡嗪酰腙衍生物的荧光探针及其制备方法和应用 | |
CN108250141B (zh) | 酪氨酸甲酯修饰n-(8-喹啉基)乙酰胺化合物、合成方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |